Clinical implementation of germ line cancer pharmacogenetic variants during the next-generation sequencing era

Clinical Pharmacology and Therapeutics

Volumn 95, Issue 3, 2014, Pages 269-280

  Gillis, N K ^a   Patel, J N ^a,b   Innocenti, F ^a,c  

^a UNC Hamner Institute for Drug Safety Sciences   (United States)

^b LEVINE CANCER INSTITUTE   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKERS; COST-BENEFIT ANALYSIS; EVIDENCE-BASED MEDICINE; GOVERNMENT AGENCIES; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; INSURANCE, HEALTH; NEOPLASMS, GERM CELL AND EMBRYONAL; PHARMACOGENETICS;

EID: 84894487280     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.214     Document Type: Article

References (75)

1. Spear, B.B., Heath-Chiozzi, M. & Huff, J. Clinical application of pharmacogenetics. Trends Mol. Med. 7, 201-204 (2001).
2. Chapman, P.B. et al.; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507-2516 (2011).
3. Shaw, A.T. et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N. Engl. J. Med. 368, 2385-2394 (2013).
4. Slamon, D.J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783-792 (2001).
5. Rosell, R. et al.; Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 13, 239-246 (2012).
6. Yang, J.C. et al. Symptom control and quality of life in LUX-Lung 3: A phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J. Clin. Oncol. 31, 3342-3350 (2013).
7. Evans, W.E. & Relling, M.V. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286, 487-491 (1999).
8. Iyer, L. et al. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin. Pharmacol. Ther. 65, 576-582 (1999).
9. Innocenti, F. et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J. Clin. Oncol. 22, 1382-1388 (2004).
10. Lennard, L., Van Loon, J.A. & Weinshilboum, R.M. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin. Pharmacol. Ther. 46, 149-154 (1989).
11. Black, A.J. et al. Thiopurine methyltransferase genotype predicts therapylimiting severe toxicity from azathioprine. Ann. Intern. Med. 129, 716-718 (1998).
12. Relling, M.V. et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J. Natl. Cancer Inst. 91, 2001-2008 (1999).
13. Relling, M.V., Pui, C.H., Cheng, C. & Evans, W.E. Thiopurine methyltransferase in acute lymphoblastic leukemia. Blood 107, 843-844 (2006).
14. Hanahan, D. & Weinberg, R.A. Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011).
15. Yang, J.J. et al. Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. JAMA 301, 393-403 (2009).
16. Innocenti, F. et al. A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303. Clin. Cancer Res. 18, 577-584 (2012).
17. Relling, M.V. & Dervieux, T. Pharmacogenetics and cancer therapy. Nat. Rev. Cancer 1, 99-108 (2001).
18. Coate, L., Cuffe, S., Horgan, A., Hung, R.J., Christiani, D. & Liu, G. Germline genetic variation, cancer outcome, and pharmacogenetics. J. Clin. Oncol. 28, 4029-4037 (2010).
19. Pinto, N., Cohn, S.L. & Dolan, M.E. Using germline genomics to individualize pediatric cancer treatments. Clin. Cancer Res. 18, 2791-2800 (2012).
20. Crona, D. & Innocenti, F. Can knowledge of germline markers of toxicity optimize dosing and efficacy of cancer therapy? Biomark. Med. 6, 349-362 (2012).
21. Wetterstrand, K. DNA Sequencing Costs: Data from the NHGRI Genome Sequencing Program (GSP). (2013). Accessed 25 July 2013.
22. Life Technologies. Life Technologies Introduces the Benchtop Ion Proton™ Sequencer; Designed to Decode a Human Genome in One Day for $1,000. (2012).
23. Simon, R. & Roychowdhury, S. Implementing personalized cancer genomics in clinical trials. Nat. Rev. Drug Discov. 12, 358-369 (2013).
24. Ramsey, L.B. et al. Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition. Genome Res. 22, 1-8 (2012).
25. Robson, M.E., Storm, C.D., Weitzel, J., Wollins, D.S. & Offit, K.; American Society of Clinical Oncology. American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. J. Clin. Oncol. 28, 893-901 (2010).
26. Markowitz, S.D. & Bertagnolli, M.M. Molecular origins of cancer: Molecular basis of colorectal cancer. N. Engl. J. Med. 361, 2449-2460 (2009).
27. Miki, Y. et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266, 66-71 (1994).
28. US Food and Drug Administration. Table of Pharmacogenomic Biomarkers in Drug Labels. . Accessed 1 July 2013.
29. McCarty, C.A. et al.; eMERGE Team. The eMERGE Network: a consortium of biorepositories linked to electronic medical records data for conducting genomic studies. BMC Med. Genomics 4, 13 (2011).
30. Kilpivaara, O. & Aaltonen, L.A. Diagnostic cancer genome sequencing and the contribution of germline variants. Science 339, 1559-1562 (2013).
31. Veenstra, D.L. et al. Improving the efficiency and relevance of evidence-based recommendations in the era of whole-genome sequencing: an EGAPP methods update. Genet. Med. 15, 14-24 (2013).
32. McLeod, H.L. Cancer pharmacogenomics: early promise, but concerted effort needed. Science 339, 1563-1566 (2013).
33. O'Donnell, P.H. & Stadler, W.M. Pharmacogenomics in early-phase oncology clinical trials: is there a sweet spot in phase II? Clin. Cancer Res. 18, 2809-2816 (2012).
34. van der Baan, F.H., Knol, M.J., Klungel, O.H., Egberts, A.C., Grobbee, D.E. & Roes, K.C. Potential of adaptive clinical trial designs in pharmacogenetic research. Pharmacogenomics 13, 571-578 (2012).
35. Relling, M.V. & Klein, T.E. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin. Pharmacol. Ther. 89, 464-467 (2011).
36. Toffoli, G. et al. Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer. J. Clin. Oncol. 28, 866-871 (2010).
37. Stanek, E.J. et al. Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey. Clin. Pharmacol. Ther. 91, 450-458 (2012).
38. O'Donnell, P.H. & Ratain, M.J. Germline pharmacogenomics in oncology: decoding the patient for targeting therapy. Mol. Oncol. 6, 251-259 (2012).
39. Bell, G.C. et al. Development and use of active clinical decision support for preemptive pharmacogenomics. J. Am. Med. Inform. Assoc. (2013); e-pub ahead of print 26 August 2013.
40. Swen, J.J. et al. Pharmacogenetics: from bench to byte. Clin. Pharmacol. Ther. 83, 781-787 (2008).
41. Pharmaceuticals and Medical Devices Agency, Japan. Record of Consultations on Pharmacogenomics/Biomarkers. (2013). Accessed 1 July 2013.
42. Swen, J.J. et al. Pharmacogenetics: from bench to byte-an update of guidelines. Clin. Pharmacol. Ther. 89, 662-673 (2011).
43. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. (2013).
44. Benson, A.B. 3rd et al. Metastatic colon cancer, version 3.2013: featured updates to the NCCN Guidelines. J. Natl. Compr. Canc. Netw. 11, 141-52; quiz 152 (2013).
45. US Food and Drug Administration. Camptosar (irinotecan) FDA label (Washington, DC, 2012). .
46. European Medicines Agency. European Public Assessment Reports. (2013).
47. Locker, G.Y. et al.; ASCO. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J. Clin. Oncol. 24, 5313-5327 (2006).
48. Relling, M.V. et al. Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update. Clin. Pharmacol. Ther. 93, 324-325 (2013).
49. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? Genet. Med. 11, 15-20 (2009).
50. Goddard, K.A. et al. Building the evidence base for decision making in cancer genomic medicine using comparative effectiveness research. Genet. Med. 14, 633-642 (2012).
51. Deverka, P.A., Vernon, J. & McLeod, H.L. Economic opportunities and challenges for pharmacogenomics. Annu. Rev. Pharmacol. Toxicol. 50, 423-437 (2010).
52. Lam, Y.W. Scientific challenges and implementation barriers to translation of pharmacogenomics in clinical practice. ISRN Pharmacol. 2013, 641089 (2013).
53. Faruki, H. Genomic testing: the clinical laboratory perspective. Clin. Pharmacol. Ther. 94, 190-192 (2013).
54. Ahmed, G. et al. Cost implications of reactive versus prospective testing for dihydropyrimidine dehydrogenase (DPD) deficiency in patients with colorectal cancer. J. Clin. Oncol. 31, abstr 3672 (2013).
55. Behl, A.S. et al. Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer. J. Natl. Cancer Inst. 104, 1785-1795 (2012).
56. Wong, W.B., Carlson, J.J., Thariani, R. & Veenstra, D.L. Cost effectiveness of pharmacogenomics: a critical and systematic review. Pharmacoeconomics 28, 1001-1013 (2010).
57. Paulden, M., Franek, J., Pham, B., Bedard, P.L., Trudeau, M. & Krahn, M. Costeffectiveness of the 21-gene assay for guiding adjuvant chemotherapy decisions in early breast cancer. Value Health 16, 729-739 (2013).
58. Abecasis, G.R. et al. An integrated map of genetic variation from 1,092 human genomes. Nature 491, 56-65 (2012).
59. Hurley, J.E. An overview of the normative economics of the health sector. In: Handbook of Health Economics Vol. 1 (eds. Culyer, A. & Newhouse, J.) 55-118 (Elsevier, The Netherlands, 2000).
60. Meric-Bernstam, F. & Mills, G.B. Overcoming implementation challenges of personalized cancer therapy. Nat. Rev. Clin. Oncol. 9, 542-548 (2012).
61. Epstein, R.S. & Teagarden, J.R. Comparative effectiveness research and personalized medicine: catalyzing or colliding? Pharmacoeconomics 28, 905-913 (2010).
62. Rocha, V. et al. Association of drug metabolism gene polymorphisms with toxicities, graft-versus-host disease and survival after HLA-identical sibling hematopoietic stem cell transplantation for patients with leukemia. Leukemia 23, 545-556 (2009).
63. Nowell, S.A. et al. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res. Treat. 91, 249-258 (2005).
64. Su, H.I. et al. Association of cyclophosphamide drug-metabolizing enzyme polymorphisms and chemotherapy-related ovarian failure in breast cancer survivors. Fertil. Steril. 94, 645-654 (2010).
65. Schwab, M. et al.; German 5-FU Toxicity Study Group. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J. Clin. Oncol. 26, 2131-2138 (2008).
66. Mellor, J.D., Brown, M.P., Irving, H.R., Zalcberg, J.R. & Dobrovic, A. A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer. J. Hematol. Oncol. 6, 1 (2013).
67. Pullarkat, S.T. et al. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J. 1, 65-70 (2001).
68. Salgado, J., Zabalegui, N., Gil, C., Monreal, I., Rodríguez, J. & García-Foncillas, J. Polymorphisms in the thymidylate synthase and dihydropyrimidine dehydrogenase genes predict response and toxicity to capecitabine-raltitrexed in colorectal cancer. Oncol. Rep. 17, 325-328 (2007).
69. Relling, M.V. et al.; Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin. Pharmacol. Ther. 89, 387-391 (2011).
70. Drugs at FDA: FDA Approved Drug Products. (2013). Accessed 1 July 2013.
71. Theriault, R.L. et al. Breast cancer, version 3.2013: featured updates to the NCCN guidelines. J. Natl. Compr. Canc. Netw. 11, 753-60; quiz 761 (2013).
72. Zelenetz, A.D. et al. Non-Hodgkin's Lymphomas, version 3.2012. J. Natl. Compr. Canc. Netw. 10, 1487-1498 (2012).
73. Alvarnas, J.C. et al.; National Comprehensive Cancer Network. Acute lymphoblastic leukemia. J. Natl. Compr. Canc. Netw. 10, 858-914 (2012).
74. Benson, A.B. 3rd et al. Rectal cancer. J. Natl. Compr. Canc. Netw. 10, 1528-1564 (2012).
75. PharmGKB: The Pharmacogenomics Knowledgebase. (2013).